Developing next-generation macromolecule therapeutics

Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement.
The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity.
This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.

Science

The Challenge: Endolysosomal trapping of macromolecules

One of the greatest challenges for efficacy of macromolecule therapeutics that act on an intracellular level, is delivery into key cells. Macromolecule therapeutics nowadays rely on receptor-mediated endocytosis into the endosomal compartment. The endo-lysosomal membranes, however, prohibit efficient cytoplasmic access of such foreign substances. The therapeutic efficacy of such drugs is therefore highly dependent on endo-lysosomal vesicles degradation.
Cytosolic delivery of macromolecule therapeutics requires incredibly challenging technical optimizations or specialized drug delivery platforms. For most oligonucleotide-based therapeutics, delivery remains an unsolved problem and exposes a significant need for the development of novel delivery mechanisms.

Our Approach: ENDOSCAPE®

At Sapreme, we are developing improved macromolecule delivery mechanisms by circumventing endosomal entrapment. Our ENDOSCAPE® platform is based on compounds which can release trapped cargo from the endo-lysosomal membranes, improving the therapeutic window and enabling access to intracellular targets with minimal toxicity.
By binding our technology to antibody-conjugated toxins and oligonucleotides, our goal is to enhance target engagement and improve therapeutic efficacy without limitation to biologic modality or indication.

News & Events

Press Releases:

January 21, 2021

Sapreme Appoints Henrik Luessen as Chief Business Officer

December 17, 2020

Sapreme Appoints Björn Cochlovius as Chairman of its Board of Directors

October 27, 2020

Sapreme Appoints Miriam Bujny as Chief Development Officer

September 28, 2020

Sapreme Unveils its Proprietary Endosomal Escape Platform in Presentations at 16th Annual Meeting of Oligonucleotide Therapeutics Society

Events:

Upcoming events:

Sapreme will be taking part in a number of conferences in September 2021. Details will be available soon.

Past events:

June 17th, 2021

Sapreme presented data at the RNAi-Based Therapeutics Summit, demonstrating the potential of its Endosomal Escape Enhancing compound SPT001 to enable superior targeted delivery of oligonucleotides.

Sapreme’s SPT001 compound significantly improves intracellular release of targeted antisense oligonucleotides (ASO’s) and thereby also their therapeutic efficacy. In addition to oligonucleotides, SPT001 has also been demonstrated to enhance delivery of other targeted payloads such as antibody-conjugated toxins.

The presentation and Q&A session was hosted on June 17^th 2021 via the summit’s virtual stage and platform.

September 28th, 2020

Guy Hermans (CEO) and Ruben Postel (CSO) presented “Efficient, targeted cytoplasmic delivery of oligonucleotides via Sapreme’s endosomal escape enhancers” and “SPT001 enhanced mAb-oligo conjugates: efficient delivery beyond the liver”, respectively, at the 16th Annual Meeting of the Oligonucleotide Therapeutics Society.

About Sapreme:

Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement. The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.

Contacts:
Guy Hermans, CEO
+31 30 760 09 76
hermans@sapreme-technologies.com

For Media Inquiries, please contact:
Trophic Communications
Eva Mulder or Valeria Fisher
+49 89 238 877 30
sapreme@trophic.eu

Careers

If you are a talented individual interested in contributing to our mission, please send your resume to

info@sapreme-technologies.com

Contact

Telephone

+31 30 760 09 76

Address

LSI, Room 2.09
Yalelaan 62
3584 CM Utrecht
The Netherlands

E-mail & LinkedIn

info@sapreme-technologies.com

Sapreme LinkedIn page